Aenova will install an additional filling and manufacturing line at the Latina, Italy, site. This expansion is an important step to meet the increasing global demand for the production of biologics.
Pace Life Sciences, a US-based contract research, development, and manufacturing organization (CRDMO), is remodeling and expanding its Salem, NH site for aseptic fill-finish processing.
Curia, a CDMO, recently shared expansion plans for facilities in Glasgow, UK, and Albuquerque, NM, US.
Quotient Sciences, a drug development and manufacturing accelerator, has invested significantly in expanding its sterile fill/finish capabilities at its Alnwick, UK facility. This expansion aims to meet the rising demand in the industry for comprehensive drug development programs by enhancing the capacity of the Annex 1-compliant facility.
The Fill & Finish of biologic drugs is expensive and poses special technological challenges for CDMOs. At the German site in Hameln, Siegfried has successfully proven these capabilities over the past two years by producing Covid-19 vaccines and a significant number of clinical batches for several biological companies. By investing in its competencies, capacities and flexibility, the company intends to further expand this demanding but promising business area.
Swiss CDMO Lonza plans to build a large-scale commercial fill & finish facility in Stein. The new facility, to be located on the same campus as Lonza’s existing clinical drug product capabilities, will cost roughly 500 million Swiss francs and should be completed in 2026.
